Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 9, 2008. The presentation will provide an overview of the Company and its clinical and research programs and is scheduled to be broadcast live on Tuesday, September 9 at 1:00 p.m. Eastern Time. The session may be accessed through the Company’s web site (www.regeneron.com on the Investor Relations page, under the Presentations heading) at the time of the presentation. An archived version of the presentation will be available after the live webcast through October 9, 2008. Additional information about Regeneron and recent news releases are available on the Regeneron worldwide web site at www.regeneron.com
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.
Regeneron Pharmaceuticals, Inc.
Investor Relations
914-345-7640
invest@regeneron.com
or
Laura
Lindsay, 914-345-7800
Corporate Communications
laura.lindsay@regeneron.com
or
Lauren
Tortorete, 212-845-5609
Media Relations
ltortorete@biosector2.com
